Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Long-Term Investments (2018 - 2023)

Profound Medical has reported Long-Term Investments over the past 6 years, most recently at $442.0 million for Q1 2023.

  • For Q1 2023, Long-Term Investments rose 346.46% year-over-year to $442.0 million; the TTM value through Mar 2023 reached $442.0 million, up 346.46%, while the annual FY2022 figure was $563000.0, 249.69% up from the prior year.
  • Long-Term Investments for Q1 2023 was $442.0 million at Profound Medical, up from $563000.0 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $442.0 million in Q1 2023 and troughed at $345.17 in Q4 2020.
  • A 5-year average of $41.8 million and a median of $267000.0 in 2021 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: plummeted 99.82% in 2020 and later skyrocketed 46543.06% in 2021.
  • Year by year, Long-Term Investments stood at $192987.1 in 2019, then plummeted by 99.82% to $345.17 in 2020, then skyrocketed by 46543.06% to $161000.0 in 2021, then surged by 249.69% to $563000.0 in 2022, then surged by 78407.99% to $442.0 million in 2023.
  • Business Quant data shows Long-Term Investments for PROF at $442.0 million in Q1 2023, $563000.0 in Q4 2022, and $72000.0 in Q2 2022.